Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial. - Gao Y; Cheng AL; Li LX; Parent N; Kichenadasse G; Karapetis CS; Rowland A; Hopkins AM; Sorich MJ (International journal of cancer, 2025)